What did Morgan Stanley change for Pfizer on March 17, 2026?

Morgan Stanley maintained a Positive stance on Pfizer on March 17, 2026 and described Atirmo Ph2 data as an incremental positive. The note did not change the formal rating level or add a new PFE price target, leaving the PFE analyst rating unchanged in level.

Does the maintained rating count as a PFE upgrade or downgrade?

No, a maintained Positive is neither an upgrade nor a downgrade. It keeps the existing view intact, so the PFE analyst rating signals ongoing confidence without a new valuation signal or price target change.

How should investors interpret the market move after the note?

The market moved about **1.38% ($0.38)** after the note, which suggests modest optimism. Investors should see the PFE analyst rating maintenance as a cue to monitor upcoming clinical milestones rather than a prompt for immediate portfolio shifts.

What does Meyka AI’s B+ grade mean for PFE investors?

Meyka AI rates PFE with a grade of B+. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. It is a summary measure and not personalized financial advice.

Analyst Ratings

Morgan Stanley Maintains Positive on Pfizer Inc. (PFE) March 2026

ByDanny Kontos March 18, 2026March 18, 2026

Morgan Stanley maintained a Positive view on Pfizer Inc. (PFE) on March 17, 2026, calling Atirmo Phase 2 data an “incremental positive.” The PFE analyst rating update was recorded at 08:39 AM and shows a reported price movement of 1.38% ($0.38) since the note. This maintained stance signals continued analyst confidence without a formal upgrade or downgrade, and it matters for investors tracking sentiment shifts around Pfizer’s clinical progress.